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Objective. To evaluate the attainability of tight risk factor control targets for three
diabetes risk factors and to assess the degree of polypharmacy required.
Data Sources/Study Setting. National Health and Nutrition Examination Survey-III.
Study Design. We simulated a strategy of ‘‘treating to targets,’’ exposing subjects to a
battery of treatments until low-density lipoprotein (LDL)-cholesterol (100 mg/dL), he-
moglobin A1c (7 percent), and blood pressure (130/80 mm Hg) targets were achieved or
until all treatments had been exhausted. Regimens included five statins of increasing
potency, four A1c-lowering therapies, and eight steps of antihypertensive therapy.
Data Collection/Extraction Methods. We selected parameter estimates from
placebo-controlled trials and meta-analyses.
Principal Findings. Under ideal efficacy conditions, 77, 64, and 58 percent of subjects
achieved the LDL, A1c, and blood pressure targets, respectively. Successful control
depended highly on a subject’s baseline number of treatments. Using the least favorable
assumptions of treatment tolerance, success rates were 11–17 percentage points lower.
Approximately 57 percent of subjects required five or more medication classes.
Conclusions. A significant proportion of people with diabetes will fail to achieve tar-
gets despite using high doses of multiple, conventional treatments. These findings raise
concerns about the feasibility and polypharmacy burden needed for tight risk factor
control, and the use of measures of tight control to assess the quality of care for diabetes.
Key Words. Quality measurement, Monte Carlo simulation, outcomes research,
diabetes mellitus
The cornerstone of diabetes care is management of risk factors for vascular
complications, particularly control of blood pressure, cholesterol, and blood
glucose. Most treatment guidelines call for lowering hemoglobin A1c below 7
percent, blood pressure below 130/80, and low-density lipoprotein (LDL)-




cholesterol below 100 mg/dL (2.59 mmol/L) (Grundy et al. 2004; American
Diabetes Association 2008). Despite demonstrating substantial health benefits,
trials that have compared tight control strategies to conventional approaches
have also consistently shown that a large proportion of patients fail to reach
targets for A1c (Abraira et al. 1995; UKPDS Study Group 1998a; Patel et al.
2008) and blood pressure (Hansson et al. 1998; UKPDS Study Group 1998b)
even after a battery of treatments. In one of the largest trials of blood glucose
control, the United Kingdom Prospective Diabetes Study (UKPDS) (UKPDS
Study Group 1998a), for example, the median A1c in the intensive treatment
group over the course of the study was 7.5 percent, meaning that most patients
were unable to achieve or maintain the 7 percent target, even though these
patients were early in the course of diabetes. In the Hypertension Optimal
Treatment (HOT) trial (Hansson et al. 1998), over half of subjects randomized
to the lowest diastolic blood pressure (DBP) target failed to reach it.
Successful control of diabetes risk factors depends on a number of fac-
tors, including a patient’s baseline value of the risk factor, the efficacy of
treatment, pathophysiological factors, treatment contraindications and side
effects, and each patient’s willingness to accept multiple and potentially bur-
densome treatments. Guidelines often emphasize the benefits of treating to
targets without consideration of their costs and side effects, and often without
reference to the potential diminishing effects of adding a third, fourth, or fifth
medication. Discontinuation rates from A1c-lowering therapies in the UKPDS
ranged from 10 to 25 percent over a 3-year period (UKPDS Study Group
1995), suggesting that the side effects or inconvenience of these treatments are
significant even among clinical trial volunteers. Little quantifiable information
exists on the necessary resources and potential harms associated with a strat-
egy of treating to target levels of risk factors. For patients having multiple
uncontrolled risk factors, the overall treatment burden could be substantial.
Although trials of intensive risk factor control often report improved health
outcomes on average, these trials often fail to provide information that is critical
for guiding decision making and policy making in the real world (Hayward,
Hofer, and Vijan 2006). First, these studies rarely report the incremental efficacy
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of each successive treatment in the intensification regimen, and without these
data, the benefits of repeatedly adding or titrating medications cannot mean-
ingfully be weighed against their harms. Second, because trial patients tend to be
healthier, more adherent, and more likely to be screened for nonresponse and
intolerance to treatment (Nallamothu, Hayward, and Bates 2008), the rate at
which targets are reached in real-world settings is likely to be significantly lower
than that observed in the clinical literature, and the polypharmacy requirements
could be much higher. We therefore developed a simulation model that inte-
grates three of the key determinants of attaining targets——efficacy of treatment,
individual variation in treatment response, and treatment tolerance——to estimate
the impact of a treat-to-target strategy for a nationally representative diabetic
population. We assess the attainability of targets across three risk factors and the
level of polypharmacy required. We conclude with a discussion of the impli-
cations of our findings for patient care and quality measurement.
METHODS
Data
We created a cohort of subjects aged 30–75 with a self-reported diagnosis of
diabetes from the third wave of the National Health and Nutrition Examination
Survey (NHANES-III). We used the third wave, fielded from 1988 to 1994,
because during this period, statins, metformin, and thiazolidinediones did not
exist or were rarely used, and antihypertensive medications were used much
less intensely (Psaty et al. 2002; McAlister et al. 2006). These factors lessen the
need to make assumptions about a subject’s medication history (e.g., contra-
indications and prior intolerances and treatment failures), or about dosing in-
formation for a subject’s current medications, neither of which are reported in
NHANES. We used multivariate imputation by chained equations (Van Bu-
uren and Oudshoorn 2007), implemented in the R language to impute missing
data (see Table SA1 for missing data rates). We accounted for the complex
sampling design of NHANES using the ‘‘Survey’’ package in R (Lumley 2008).
Treatments
We specified risk factor–specific intensification regimens that differed accord-
ing to a subject’s baseline medications (Table 1). Subjects having LDL levels
above target at baseline (100 mg/dL [2.59 mmol/L]) and receiving either no
treatment or treatment with lipid-lowering drugs other than statins were started
on a low-dose statin that was sequentially titrated (a maximum of five treatment
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steps). We assumed those who were already taking a statin at baseline were on a
low dose. Treatments used to lower A1c below 7 percent included metformin,
sulfonylurea, glitazone, and insulin. Although the 7 percent threshold is no
longer recommended in the elderly population, it was a common target for all
populations at the beginning of this study. We assumed subjects who were
taking sulfonylurea or insulin at baseline were on submaximal doses, so we
included titration steps for both therapies. Subjects having either a systolic
blood pressure (SBP) above 130 mm Hg or a diastolic blood pressure (DBP)
above 80 mm Hg and who were untreated at baseline were consecutively
treated with a thiazide, ACE inhibitor, beta blocker, and calcium channel
blocker. Subjects self-reporting antihypertensives at baseline were assumed to
be receiving standard doses, and drug classes were added in the aforemen-
tioned order as needed. Those remaining above the target after receiving
standard doses of each medication were intensified with double doses.
Model Parameters
Mean Treatment Efficacy. The bulk of our treatment efficacy parameters came
from two published meta-analyses of randomized placebo-controlled trials, and
a meta-analysis that we performed ourselves (Tables SA2–SA4). Law, Wald,
and Rudnicka (2003b) pooled 72 simvastatin treatment groups and 24
atorvastatin groups, and a second meta-analysis by Law et al. (2003a)
included 104 thiazide treatment groups, 217 ACE inhibitor groups, 136 beta
blocker groups, and 209 calcium channel blocker groups. For each treatment
we abstracted difference-in-difference estimates (mean absolute or relative
reductions in each risk factor for the treatment group relative to placebo) along
with their standard errors. Because the efficacy of A1c-lowering treatments
depended on the types of drugs a subject was already taking, we conducted our
own meta-analysis to estimate the efficacy of A1c-lowering treatments for a
broad range of two-drug combinations. To determine the efficacy of adding a
third or fourth antihyperglycemic therapy to a subject’s existing regimen, for
which few reliable estimates were found in the literature, we compared the
efficacy of the treatment in question when added as the second drug in a two-
drug combination with each treatment in the existing regimen. We then selected
the minimum estimate to serve as an upper bound for the efficacy of the three-
drug combination. For example, the efficacy of metformin added to a regimen
consisting of insulin and sulfonylurea was estimated to be 6.4 percent, since
patients on sulfonylurea and those on insulin had reductions of 6.4 and 12.5
percent, respectively, when metformin was added to each monotherapy.
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Among antihypertensives, Wu et al. (2005) demonstrated that
combination therapy, on average, resulted in a 16/35 percent lower efficacy
(systolic/diastolic) relative to monotherapy. We extended this finding to
incorporate a diminishing marginal efficacy for each additional agent used, so
that, whereas a second agent added would have 84 percent of the expected
(systolic) efficacy, a third and fourth would have 71 percent (0.842) and 59
percent (0.843) of the efficacy of monotherapy. In sensitivity analyses, we used a
constant relative efficacy——16/35 percent lower efficacy for all antihypertensives.
We modeled treatment efficacy as a percentage change in each risk factor
from baseline to account for larger treatment effects for subjects with elevated risk
factors at baseline. Studies typically reported absolute changes in risk factors for
A1c and blood pressure treatments, so we estimated relative changes by dividing
each efficacy estimate by the baseline risk factor level in each treatment group.
Variance in Treatment Efficacy. We found no meta-analyses that pooled
estimates of between-subject variance in treatment efficacy. For the variance
in statin efficacy, we pooled variance estimates from a large number of
individual studies. For A1c and blood pressure treatments, however, variance
estimates were reported only on the absolute scale, so we adopted an ecological
approach and estimated the variance in relative reductions at the study level to
serve as a surrogate for the patient-level variance. Because the between-study
variance will underestimate the between-patient variance, our base case analysis
assumed that the range in efficacy estimates from the contributing studies was
approximately equal to 1 standard deviation in patient-level variability, or
in other words, about 70 percent of the patient-level variation was contained
in the interval defined by the range of study-level estimates. In sensitivity
analyses we defined the patient-level variance to be equal to the study-level
variance. We derived coefficients of variation (CV) for each treatment, defined
as the ratio of the standard deviation in efficacy to the mean treatment efficacy to
allow us to crosswalk any simulated mean efficacy parameter to a variance
estimate by simply taking the product of the mean efficacy and the CV.
Treatment Discontinuation. We used treatment discontinuation rates to
measure patients’ intolerance to treatment. Discontinuation rates reflect
both the side effects and burdens of treatment, including polypharmacy, the
inconvenience of injection therapy, and potentially cost burdens. We used
all-cause discontinuation rates from several large statin trials, our own meta-
analysis of A1c-lowering treatments, and a meta-analysis of discontinuation
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rates for antihypertensives (Ross et al. 2001). Using results from the IDEAL
trial (back-titration rate from atorvastatin 80 mg of 13 percent and
discontinuation rate of 5.4 percent), we specified back-titration
and discontinuation rates following the initiation of both atorvastatin 40 and
80 mg to be 6.5 and 2.7 percent, respectively (Pedersen et al. 2005). We found no
relationship between dose and discontinuation rates for antihypertensives
(Materson et al. 1993). We assumed that subjects who were titrated from
submaximal doses of sulfonylurea and insulin would not discontinue treatment
on a higher dose but would only back-titrate to the baseline dose at half the
discontinuation rate reported for those initiating each therapy.
Simulation
We used Monte Carlo simulation to integrate the treatment efficacy and dis-
continuation parameters into a model of the effectiveness of a treat-to-target
strategy. First, we sampled a mean efficacy estimate for each treatment and
then calculated the standard deviation as the product of the mean and CV.
Using these estimates and assuming that treatment responses in the population
were normally distributed, we randomly sampled percentage reductions for
each subject for each step 1 therapy. We then computed each subject’s new
risk factor level and assessed whether each target was attained. We repeated
these steps for each subject until the target was reached or until all treatments
had been exhausted. We simulated discontinuation from each drug class and
assumed subjects who discontinued received no treatment benefit. We ran 500
simulations of the model to capture uncertainty in all parameters.
By using discontinuation rates and adherence levels from randomized
controlled trials, our base case analysis provides the most favorable estimates
of target attainment. In sensitivity analyses, we increased discontinuation rates
by 5 and 10 percentage points and limited risk factor reductions to 90 and 80
percent of their simulated values to mimic poorer adherence. We then varied
both parameters simultaneously to compare levels of attainment for a ‘‘less
favorable’’ and a ‘‘least favorable’’ scenario.
RESULTS
The weighted NHANES-III data provide nationally representative estimates
for the diabetic population of the early 1990s, comprised of nearly 8 million
individuals between the ages of 30 and 75. Baseline characteristics of the
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population are reported in Table SA1, and all efficacy and discontinuation
parameters are listed in Tables SA2–SA4. The incremental efficacy of each
statin dose beyond step 1 decreased monotonically (with the exception of
simvastatin 40 mg), ranging from a 32.1 percent reduction for simvastatin
20 mg, to a reduction of 5.7 percent for combination therapy with ezetimibe.
Relative reductions in A1c tended to be much larger for treatments used as
monotherapy (range: 11.8 percent [glitazone] to 14.9 percent [sulfonylurea]),
compared with the efficacy of each drug when used in combination (range: 6.4
percent [adding metformin to sulfonylurea] to 12.9 percent [adding glitazone
to sulfonylurea]). Adding insulin to oral therapy had the greatest efficacy,
reducing A1c levels by 17.6 percent. When used as monotherapy, each stan-
dard dose of antihypertensive therapy had comparable efficacy in lowering
SBP, 5.5–6.0 percent (8.5–9.2 points), while DBP reductions ranged from 4.5
to 6.9 percent (4.4–6.7 points). Double doses of each drug had on average less
than one-third the efficacy of standard doses. When accounting for the di-
minishing benefit of combination therapy, however, the effective reductions in
SBP were smaller: 5.7, 4.6, 4.2, and 3.4 percent, for thiazides, ACE-inhibitors,
beta blockers, and calcium channel blockers, for a subject on no medications
at baseline. DBP reductions were 4.5, 3.1, 2.9, and 1.7 percent, respectively.
The between-subject variation in treatment efficacy, based on our own
meta-analysis (Tables SA2–SA4) varied between treatments for each risk fac-
tor as well as between risk factors. The coefficient of variation, which expresses
the ratio of the standard deviation in efficacy to the mean efficacy, was 40
percent for statin therapy. For a treatment that lowers LDL by 32 percent on
average, this implies that roughly 20 percent of subjects would experience a
reduction of 21 percent or less and 20 percent would have more than a 43
percent reduction. Coefficients of variation for A1c-lowering treatments
ranged from 23 percent (adding glitazone to sulfonylurea) to 76 percent (add-
ing metformin to sulfonylurea). Response heterogeneity was larger for the
blood pressure treatments. Coefficients of variation ranged from 44 to 66
percent for SBP and 54 to 72 percent for DBP.
In Table 2, we report the results of our base case analysis. At the time of
NHANES-III, 90 percent of subjects with elevated LDL levels were on no
cholesterol-lowering treatment, and the mean LDL of these subjects was
150 mg/dL. About 46 percent of subjects were taking only a sulfonylurea
(mean A1c, 9.2 percent), while 30 percent took only insulin (mean A1c,
9.4 percent). Forty-three percent took no antihypertensives (mean BP,
142/79 mm Hg), 32 percent were being treated with a single drug class
(mean BP, 145/78 mm Hg), and 22 percent were on two classes (mean BP,
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146/81 mm Hg). Treatment was generally effective in reducing risk factor
levels, but many subjects did not achieve targets even when titrated to max-
imal doses. Overall target attainment was 77.0 percent for LDL, 63.6 percent
for A1c, and 57.9 percent for blood pressure. The mean reduction in LDL
among naı̈ve subjects was 55 points, but 22 percent of these subjects failed to
achieve targets. Those already on lipid-lowering therapy had lower levels of
attainment (51–77 percent), even with maximal doses of potent statins. A1c
treatment was effective in achieving targets for fewer subjects; those on no
therapy at baseline achieved targets 80 percent of the time, but the majority of
subjects who were already on glucose-lowering agents achieved targets only
32–68 percent of the time. Similarly, blood pressure targets were achieved
between 0.3 percent of the time (those on four agents at baseline) and 78
percent of the time (those on no agents at baseline). Among subjects under-














No treatment 89.8 149.8 mg/dL 54.9 1.8 78.2 2.7
Non statin 5.9 153.0 mg/dL 57.4 5.6 77.0 8.5
Low-dose statin 4.3 159.6 mg/dL 47.0 8.4 50.5 13.1
Overall 150.4 mg/dL 54.7 —— 77.0 ——
A1c
No treatment 21.9 9.0% 2.3 0.1 80.0 4.2
Sulfonylurea
only
45.9 9.2% 2.1 0.1 68.4 3.4
Insulin only 29.8 9.4% 1.9 0.1 47.0 6.2
Sulfonylurea and
insulin
2.5 9.7% 1.5 0.3 31.5 8.5
Overall 9.2% 2.1 —— 63.6 ——
BP
No treatment 42.5 141.6, 78.7 mm Hg  16.1,  6.6 0.4, 0.2 78.2 2.3
1 class 31.7 145.4, 77.8 mm Hg  15.0,  4.9 0.5, 0.2 56.8 2.6
2 classes 21.6 146.1, 80.7 mm Hg  12.2,  3.6 0.7, 0.2 27.4 3.5
3 classes 3.5 154.8, 80.1 mm Hg  8.7,  2.1 1.0, 0.2 19.2 4.0
4 classes 0.6 141.6, 87.9 mm Hg  4.4,  1.2 1.0, 0.3 0.3 2.3
Overall 144.2, 78.9 mm Hg  14.6,  5.2 —— 57.9 ——
Note. Targets were 100 mg/dL (2.59 mmol/L) (LDL), 7% (A1c), and 130/80 mm Hg (blood pres-
sure). Measurement scale for absolute treatment effect is same as that of baseline level. Results for
blood pressure are systolic, diastolic.
nAcross 500 model simulations.
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going intensification for at least one risk factor 44.3 percent ultimately
achieved all three targets.
We found significantly lower rates of attainment when we changed our
assumptions about the expected level of tolerance patients might exhibit in
nonexperimental settings. As shown in Table 3, when we inflated discontin-
uation rates by an additional 5 and 10 percentage points, target attainment
rates fell by about 4 and 8 percentage points, respectively, for both LDL and
A1c but less so for blood pressure. Lower adherence rates had a large effect on
target attainment for all three risk factors. When the least favorable assump-
tions were incorporated, attainment decreased by 11–17 percentage points










Favorablew15% 110% 90% 80%
LDL
No treatment 78.2  4.8  9.3  3.1  7.2  7.7  15.6
Nonstatin 77.0  5.0  9.7  4.0  7.7  7.7  16.2
Low-dose
statin
50.5  1.0  0.6  4.8  9.8  5.6  11.5
Overall 77.0  4.6  9.0  3.2  7.4  7.6  15.5
A1c
No treatment 80.0  3.0  6.1  4.2  9.9  7.5  15.8
Sulfonylurea
only
68.4  3.7  7.5  5.0  10.4  8.3  17.4
Insulin only 47.0  3.1  7.0  6.6  13.5  9.6  18.8
Sulfonylurea
and insulin
31.5  2.6  5.6  3.3  6.2  6.0  10.4
Overall 63.6  3.3  7.0  5.2  11.1  8.5  17.3
BP
No treatment 78.2  2.1  4.2  4.1  8.7  5.8  13.1
1 class 56.8  2.0  3.9  4.1  8.0  5.6  11.9
2 classes 27.4  1.4  2.5  3.4  6.9  4.2  8.9
3 classes 19.2  0.5  1.3  1.2  2.1  1.8  3.2
4 classes 0.3 0.2 0.0  0.3  0.3  0.3  0.3
Overall 57.9  1.8  3.6  3.8  7.8  5.3  11.4
Note. Alternative coefficient of variation parameters resulted in incremental target attainment rates
of 0.7 percentage points (A1c) and 1.2 percentage points (BP). When we incorporated a constant
16%/35% lower systolic/diastolic efficacy for any blood pressure treatment used in combination,
target attainment for blood pressure increased by 9.0 percentage points.
nIncludes 5 percentage points additional discontinuation and 90% adherence.
wIncludes 10 percentage points additional discontinuation and 80% adherence.
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across the three risk factors, giving success rates of 62 percent for LDL, 46
percent for A1c, and 46 percent for blood pressure.
Among those undergoing intensification for at least one elevated risk
factor, over half of the population required five or more medications to sustain
their final levels (results not shown). Thirteen percent of the population re-
quired combination statin therapy, 21, 26, and 38 percent required 2, 3, and 4
or more A1c-lowering drug classes, respectively, while 38 percent needed all
four antihypertensive treatments. Poor tolerance caused subjects undergoing
intensification to need greater amounts of treatments downstream in the reg-
imen, particularly high-dose medications (Figure 1). When we used our least
favorable assumptions about tolerance, utilization of statin-combination ther-
apy was 3.2 percentage points higher, use of glitazones and insulin increased
by 2.1 and 5.9 percentage points, respectively, and use of high-dose antihy-
pertensives rose between 6.7 and 7.1 percentage points.
Individual variation in response to treatment also affected the level of
polypharmacy required, albeit for a much smaller fraction of the population.
In Figure 2, we display the average number of intensifications required by
those subjects untreated at baseline for each risk factor. For patients with a
baseline LDL ranging from 100 to 120, 91.6 percent of subjects required only
one intensification to reach targets, while 5.5 percent required three or more.
Among those subjects with a baseline A1c between 7 and 8, 2.2 percent
needed three or more agents because of variance in response to treatment. The
majority of subjects having mild hypertension needed four or fewer intensi-
fications, but 19.3 percent required five or more.
DISCUSSION
Using results from clinical trials, we developed a simulation model to assess the
likelihood a nationally representative diabetes cohort could achieve commonly
cited risk factor targets through the repeated intensification of medications. Our
model accounted for three factors likely to determine the success of treating to
targets——the efficacy of stepped combination therapy in lowering the risk factor,
and heterogeneity in treatment response and treatment tolerance. Each of these
factors is rarely reported in the results of treat-to-target trials, but all are key to
generalizing their findings to larger populations. In our review of the literature,
we found that almost all treatments had a diminishing relative efficacy when
combined with other medications. For an untreated subject at baseline,
ezetimibe combination therapy had only 8 percent of the absolute reduction of
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simvastatin 20 mg, adding a glitazone as a third oral medication was 52 percent
as effective as metformin monotherapy, and adding a fourth antihypertensive
medication provided only 51 percent of the systolic efficacy of the first med-
ication. The diminishing absolute reductions of treatment intensification result
from the dual effects of the second, third, and fourth medications having a
progressively inferior relative impact on the patient’s risk factor as well as a
patient’s diminishing pretreatment levels of each risk factor. We also found that
variation in patients’ responses to treatment and poor tolerance of treatment,
even assuming levels of discontinuation and adherence in randomized con-











































































































Figure 1: Distribution of Treatments Following Intensification for Two
Levels of Assumed Tolerance to Treatment
Note. Simulation results that assumed tolerance levels of randomized controlled trials are
depicted with solid bars. Striped bars reflect the least favorable tolerance assumptions (10 per-
centage points higher discontinuation and 80 percent adherence relative to randomized trials). All
results reflect the subpopulation of subjects on no treatments at baseline and assume that met-
formin is not contraindicated for any subject.
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targets. Finally, a treat-to-target strategy required lifetime treatment with sub-
stantial polypharmacy just for treating these three conditions.
Target attainment rates were low despite a number of assumptions we
made that were favorable to larger risk factor reductions. First, we most likely
overstated the benefits of combination therapy involving three or more
A1c-lowering treatments by assuming a third drug added to a two-drug
regimen had the same efficacy as when added to monotherapy. The paucity of
evidence in the literature on these effect sizes and the lack of any data on
combinations of three or more antihypertensive drugs is concerning given the
widespread recommendation to treat-to-target without consideration of the
amount of risk factor reduction achieved with progressively greater poly-
pharmacy. Second, we assumed that any medication not reported as being
currently taken by a subject in NHANES had never been taken and was
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Figure 2: Differences in the Number of Intensifications Required Due to
Between-Subject Variability in Treatment Response for Subjects with
Moderate and Poor Risk Factor Control at Baseline
Note. White bars correspond to subjects with moderate risk factor control. Black bars corre-
spond to subjects with poor control. All results reflect the subpopulation of subjects on no treat-
ments at baseline, assume zero discontinuation and 100 percent adherence, and assume that
metformin is not contraindicated for any subject.
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trials. Some subjects, however, might have used medications in the past but
discontinued them due to a poor response or poor tolerance. Third, we as-
sumed that subjects who were taking medications at baseline did not discon-
tinue their use over the intensification period. Fourth, we did not account for
lower adherence and higher discontinuation rates that might be expected for
subjects with higher levels of polypharmacy. Finally, though our base case
results assumed adherence levels of patients enrolled in trials, we did not
account for case management strategies that are commonly used in clinical
practice today. If these interventions improve adherence rates beyond those
typically found in trials, we might have underestimated levels of goal attain-
ment and overstated our polypharmacy results.
In the absence of certain parameter estimates or conventions, we were
forced to make several simplifications that might affect our model’s validity.
First, there is no one standard treatment protocol for patients having elevated
blood pressure, A1c, and LDL levels, and using different treatments or a
greater number of therapies beyond what we considered could impact our
results. We might have included additional classes of antihyperglycemics,
such as GLP-1 analogs (e.g., Bayetta), or antihypertensives, such as minoxidil,
particularly for subjects who could not tolerate standard treatments, but we
restricted our focus to treatments considered to be part of standard care in
most practice settings. We excluded fibrate therapy because these agents
generally are prescribed to lower triglycerides and increase high-density lipo-
protein (HDL), and they have limited efficacy in lowering LDL (Rubins et al.
1999) or reducing cardiovascular disease mortality (Saha et al. 2007).
Second, rather than assuming that patients’ therapies are always inten-
sified, we might have incorporated treatment substitutions, particularly
for those subjects having a poor clinical response to a new therapy. Doing
so would have resulted in lower levels of polypharmacy but not lower levels of
risk factor control if the set of available treatments remained fixed. Modeling
the substitution of treatments is complicated, however, and in practice, there
could be wide variation between physicians in the rates with which drugs are
switched, added, and intensified.
Third, lacking individual-level data to more fully understand the shape
of treatment efficacy distributions, we used a standard assumption of normal-
ity. And because we did not have variance estimates on the relative scale, we
used an ecological estimate of variance that likely caused us to underestimate
the true level of variability. Nevertheless, we showed that some patients with
moderate control required a disproportionate amount of treatment due to
individual variability in response to treatment.
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The absolute level of tight control attained by the NHANES-III cohort
might differ from levels based on more recent waves of the survey. Without
detailed information on patients’ treatment histories or their current doses,
however, estimating the expected level of attainment in the current U.S. diabetic
population would require considerable extrapolation. Furthermore, because of
changes in the composition of the diabetic population over time the implications
for the level of goal attainment are unclear. While our results apply to a specific
population at a specific point in time, the factors that contribute to the attainment
of targets——diminishing effectiveness of combination therapy and variation in
treatment response and tolerance——are generalizable across time.
These results have important implications for both patient care and
quality measurement. First, patients will require significant levels of poly-
pharmacy to reach tight control targets. Since nearly half of the NHANES-III
cohort required five or more medications, the side effect rate and overall
treatment burden for patients are likely to be high, though our analysis did not
explicitly measure these effects. There is little data on the relationship between
polypharmacy and a patient’s side effect burden for combinations of three or
more drugs, let alone five or more. Although tight control targets are critical
elements of practice guidelines and can help guide clinical practice, our results
suggest that the risks of treating to targets should be carefully weighed with the
benefits at the individual level. For patients who are already on multiple
medications and remain slightly above risk factor targets——arguably the most
common scenario——the net benefit of intensifying treatment is unclear. It also
remains unclear whether patients in typical clinic settings will be willing to
tolerate the out-of-pocket costs, time costs, risks and burdens of polyphar-
macy, and indeed whether our health system can support the personnel and
treatment costs required for monitoring risk factor levels, titrating medica-
tions, and managing side effects. Combination medications would lower the
polypharmacy burden, but not the incidence of side effects and other safety
risks such as drug–drug interactions.
Second, these results highlight potential limitations to the use of inter-
mediate outcomes as quality measures. We have shown that the attainment of
targets depends in large part on three factors that are unrelated to the quality of
care, and that the attainment of targets in nonexperimental settings will be
much more difficult despite the use of a broad range of highly potent treat-
ments. Subjects receiving multiple treatments at baseline had a much lower
likelihood of reaching targets despite having sizable absolute reductions in risk
factors. Under such circumstances, current quality measures could create in-
centives to avoid these patients and cherry pick patients that are more likely to
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reach targets. Risk adjustment models developed to allow ‘‘fair’’ comparisons
of performance have so far proven inadequate (Zhang et al. 2000; Thompson
et al. 2005; Kaplan et al. 2009). Although few have looked at the unintended
consequences of publicly reporting intermediate outcomes, evidence from
other clinical areas raises concerns about the potential for risk selection to
avoid patients likely to have poor outcomes (Werner, Asch, and Polsky 2005).
Alternative quality measures such as ‘‘linked action measures’’ (Kerr
et al. 2001, 2003) have been proposed to compensate for the limitations of
intermediate outcome measures of quality. These measures define quality stan-
dards as either the attainment of a risk factor target or the timely intensification of
therapy for an uncontrolled risk factor, while also accounting for a limited set of
exceptions, such as the use of high-dose medications at baseline and allowing
follow-up measurements to account for measurement error. Others have argued
that quality measures should require more explicit considerations of the risks
and benefits of the treatments required (Krumholz and Lee 2008).
We limited our intensification regimen to common treatments——statins,
four classes of A1c-lowering agents, and four classes of antihypertensives——but
these treatments were ineffective in helping a large share of the population
attain targets. A particular concern in light of recent safety problems (Nissen
and Wolski 2007) and efficacy questions (Kastelein et al. 2008) is that pro-
viders might be encouraged to rely more heavily on the expanding list of
newer medications——beyond those considered in this analysis——for patients
who remain refractory to standard treatments. New drugs generally have
poorly established safety profiles (Food and Drug Administration 2000; Lasser
et al. 2002), lack evidence of benefit for the most clinically important outcomes
(Fleming and DeMets 1996), and are much more costly. While these treat-
ments may have some role in the care of patients who are at highest risk of
adverse outcomes, the pursuit of tight risk factor control targets will require
that they be used at much higher rates, and the relative benefits and risks of
doing so should first be clearly defined.
CONCLUSION
The diminishing efficacy of polypharmacy and heterogeneity in patients’
clinical response to and tolerance of common treatments to control diabetes
risk factors implies that the average patient will require multiple classes of
medications, and a significant fraction will fail to achieve tight control with
standard treatments even under ideal efficacy conditions. In practice, a far
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greater share of the population will remain above targets in spite of intensive
treatment, increasing the likelihood that patients will be exposed to the bur-
dens and risks of polypharmacy. Performance measures that define standards
by the attainment of tight risk factor control ignore potential treatment efficacy
constraints, biological variability, and the escalating side effects and burdens
associated with polypharmacy.
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